神経性食欲不振症市場：治療タイプ、年齢層、重症度、エンドユーザー、治療チャネル別-2025-2030年世界予測

神経性食欲不振症市場は、2023年に9,465万米ドルと評価され、2024年には1億687万米ドルに達すると予測され、CAGR 13.27％で成長し、2030年には2億2,652万米ドルに達すると予測されています。

神経性食欲不振症は、太ることへの強い恐怖と歪んだ身体イメージを特徴とする重度の摂食障害であり、食事制限と過度の体重減少につながります。神経性食欲不振症に取り組む必要性は、栄養失調、心臓の問題、さらには死亡率など、その深刻な健康への影響から生じる。この領域の市場調査の用途には、患者の人口統計、ヘルスケアアプローチ、治療手法の理解が含まれ、最終用途の範囲には、ヘルスケアプロバイダー、メンタルヘルス専門家、医薬品が含まれます。主な成長要因は、メンタルヘルス問題に対する意識の高まり、治療介入の進歩、ヘルスケア規制の支援です。潜在的なビジネスチャンスは、遠隔患者モニタリングのための遠隔医療サービスの拡大、効果的な投薬における医薬品開発、AIとデータ分析を活用した個別化治療計画にあります。しかし、市場の成長は、メンタルヘルスに付随する社会的偏見、高額な治療費、訓練を受けた専門家の不足といった限界に直面しています。物流上の制約や規制上のハードルが、市場力学をさらに複雑にしています。

このような機会を活用するために、企業は継続的なサポートや治療のためのデジタルヘルスプラットフォームの革新、マインドフルネスや栄養精神医学のような非伝統的でホリスティックな治療アプローチの調査、メンタルヘルス擁護団体との連携に注力すべきです。さらに、モバイル・ヘルス・テクノロジーは、若年層への早期介入と啓発をターゲットにすることができます。市場の性質はダイナミックで、競争が激化し、包括的で利用しやすい治療ソリューションが求められています。企業は、個別化医療に大きく貢献する、神経性食欲不振症に影響を与える遺伝的要因に関する調査を強化すべきです。ウェアラブル技術のような高度な診断ツールのためのハイテク企業との戦略的パートナーシップの構築は、リアルタイムの健康モニタリングを提供し、それによって患者の転帰とエンゲージメントを改善することができます。全体として、強固な市場戦略と先進技術の融合は、市場機会の獲得と既存の課題の克服に大きく貢献する可能性があります。

市場力学：急速に進化する神経性食欲不振症市場の主要市場インサイトを公開

神経性食欲不振症市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 神経性食欲不振症患者の治療におけるオンラインおよびデジタル療法の役割の拡大
  • メンタルヘルス研究と治療プログラムに対する政府の取り組みと資金提供
  • 包括的な患者ケアのための栄養士、心理学者、医師を含む学際的アプローチの統合
• 市場抑制要因
  • 神経性食欲不振症を取り巻く高い偏見と認識不足が早期診断と早期介入を妨げる
• 市場機会
  • 人工知能の活用による神経性食欲不振症の早期発見・診断の改善
  • 神経性食欲不振症患者の回復をサポートするための標的栄養プログラムの開発
• 市場の課題
  • 神経性食欲不振症に対する効果的な治療オプションが限られているため、広範な回復が妨げられる

ポーターの5つの力：神経性食欲不振症市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、神経性食欲不振症市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：神経性食欲不振症市場における外部からの影響の把握

外部マクロ環境要因は、神経性食欲不振症市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析神経性食欲不振症市場における競合情勢の把握

神経性食欲不振症市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス神経性食欲不振症市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、神経性食欲不振症市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨神経性食欲不振症市場における成功への道筋を描く

神経性食欲不振症市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 患者治療におけるオンラインおよびデジタル療法の役割の拡大神経性食欲不振症
    • メンタルヘルス調査および治療プログラムに対する政府の取り組みと資金提供
    • 栄養士、心理学者、医師を含む多分野にわたるアプローチを統合し、包括的な患者ケアを実現する
  • 抑制要因
    • 神経性食欲不振症に関する高い偏見と認識の欠如は、早期診断と介入を妨げている
  • 機会
    • 人工知能を活用して神経性食欲不振症の早期検出と診断を改善する
    • 神経性食欲不振症患者の回復をサポートするためにターゲットを絞った栄養プログラムの開発
  • 課題
    • 神経性食欲不振症に対する有効な治療選択肢が限られているため、広範囲にわたる回復が妨げられている
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 神経性食欲不振症市場治療の種類別

• 栄養カウンセリング
• 薬物療法
  • 抗うつ薬
  • 抗精神病薬
  • 気分安定剤
• 心理療法
  • 認知行動療法
  • 家族療法
  • 対人関係心理療法

第7章 神経性食欲不振症市場：年齢層別

• 大人
• 子どもと青少年

第8章 神経性食欲不振症市場重大度レベル別

• 軽度
• 適度
• 重度

第9章 神経性食欲不振症市場：エンドユーザー別

• クリニック
• ホームケア
• 病院

第10章 神経性食欲不振症市場治療チャンネル

• 入院患者
• 外来患者

第11章 南北アメリカの神経性食欲不振症市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域の神経性食欲不振症市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの神経性食欲不振症市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • 270万ユーロの新しい調査イニシアチブは、摂食障害、自傷行為、自閉症の関連性を調査し、若者の早期診断と介入を改善することを目指しています。
  • Equipがバーチャル摂食障害治療サービスを拡大するための追加資金を確保
  • カリフォルニア大学サンディエゴ校は、ケトン体療法の再発予防に対する有効性を調べるために235,000ドルの寄付金で臨床試験を開始しました。
• 戦略分析と提言
  • メルク社

企業一覧

• Alkermes plc
• Amgen Inc.
• Biohaven Pharmaceuticals
• Hologic, Inc.
• Johnson & Johnson
• Merck & Co., Inc.
• Mindstrong Health
• Otsuka Pharmaceutical Co., Ltd.
• Pfizer Inc.
• PsychoGenics Inc.
• Sanofi S.A.
• Sumitomo Pharma America, Inc.
• Takeda Pharmaceutical Company Limited.
• Tonix Pharmaceuticals Holding Corp.

LIST OF FIGURES

• FIGURE 1. ANOREXIA NERVOSA MARKET RESEARCH PROCESS
• FIGURE 2. ANOREXIA NERVOSA MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ANOREXIA NERVOSA MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 19. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. ANOREXIA NERVOSA MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 25. ANOREXIA NERVOSA MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ANOREXIA NERVOSA MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ANOREXIA NERVOSA MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ANOREXIA NERVOSA MARKET DYNAMICS
• TABLE 7. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY NUTRITIONAL COUNSELING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ANTIPSYCHOTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY MOOD STABILIZERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY FAMILY-BASED THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY INTERPERSONAL PSYCHOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY CHILDREN & ADOLESCENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY MILD, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY MODERATE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SEVERE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY IN-PATIENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY OUT-PATIENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 38. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 39. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
• TABLE 40. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 41. ARGENTINA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 42. ARGENTINA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 43. ARGENTINA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 44. ARGENTINA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 45. ARGENTINA ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 46. ARGENTINA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 47. ARGENTINA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
• TABLE 48. BRAZIL ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 49. BRAZIL ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 50. BRAZIL ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 51. BRAZIL ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 52. BRAZIL ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 53. BRAZIL ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 54. BRAZIL ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
• TABLE 55. CANADA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 56. CANADA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 57. CANADA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 58. CANADA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 59. CANADA ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 60. CANADA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 61. CANADA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
• TABLE 62. MEXICO ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 63. MEXICO ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 64. MEXICO ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 65. MEXICO ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 66. MEXICO ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 67. MEXICO ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 68. MEXICO ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
• TABLE 69. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 70. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 71. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 72. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 73. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 74. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 75. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
• TABLE 76. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 77. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 78. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 79. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 80. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 81. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 82. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 83. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
• TABLE 84. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 85. AUSTRALIA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 86. AUSTRALIA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 87. AUSTRALIA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 88. AUSTRALIA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 89. AUSTRALIA ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 90. AUSTRALIA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 91. AUSTRALIA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
• TABLE 92. CHINA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 93. CHINA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 94. CHINA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 95. CHINA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 96. CHINA ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 97. CHINA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 98. CHINA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
• TABLE 99. INDIA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 100. INDIA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 101. INDIA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 102. INDIA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 103. INDIA ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 104. INDIA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 105. INDIA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
• TABLE 106. INDONESIA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 107. INDONESIA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 108. INDONESIA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 109. INDONESIA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 110. INDONESIA ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 111. INDONESIA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 112. INDONESIA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
• TABLE 113. JAPAN ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 114. JAPAN ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 115. JAPAN ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 116. JAPAN ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 117. JAPAN ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 118. JAPAN ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 119. JAPAN ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
• TABLE 120. MALAYSIA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 121. MALAYSIA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 122. MALAYSIA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 123. MALAYSIA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 124. MALAYSIA ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 125. MALAYSIA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 126. MALAYSIA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
• TABLE 127. PHILIPPINES ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 128. PHILIPPINES ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 129. PHILIPPINES ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 130. PHILIPPINES ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 131. PHILIPPINES ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 132. PHILIPPINES ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 133. PHILIPPINES ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
• TABLE 134. SINGAPORE ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 135. SINGAPORE ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 136. SINGAPORE ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 137. SINGAPORE ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 138. SINGAPORE ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 139. SINGAPORE ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 140. SINGAPORE ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
• TABLE 141. SOUTH KOREA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 142. SOUTH KOREA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 143. SOUTH KOREA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 144. SOUTH KOREA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 145. SOUTH KOREA ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 146. SOUTH KOREA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 147. SOUTH KOREA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
• TABLE 148. TAIWAN ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 149. TAIWAN ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 150. TAIWAN ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 151. TAIWAN ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 152. TAIWAN ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 153. TAIWAN ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 154. TAIWAN ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
• TABLE 155. THAILAND ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 156. THAILAND ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 157. THAILAND ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 158. THAILAND ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 159. THAILAND ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 160. THAILAND ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 161. THAILAND ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
• TABLE 162. VIETNAM ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 163. VIETNAM ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 164. VIETNAM ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 165. VIETNAM ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 166. VIETNAM ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 167. VIETNAM ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 168. VIETNAM ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
• TABLE 169. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 170. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 171. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 172. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 173. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 174. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 175. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
• TABLE 176. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 177. DENMARK ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 178. DENMARK ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 179. DENMARK ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 180. DENMARK ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 181. DENMARK ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 182. DENMARK ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 183. DENMARK ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
• TABLE 184. EGYPT ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 185. EGYPT ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 186. EGYPT ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 187. EGYPT ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 188. EGYPT ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 189. EGYPT ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 190. EGYPT ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
• TABLE 191. FINLAND ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 192. FINLAND ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 193. FINLAND ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 194. FINLAND ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 195. FINLAND ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 196. FINLAND ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 197. FINLAND ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
• TABLE 198. FRANCE ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 199. FRANCE ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 200. FRANCE ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 201. FRANCE ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 202. FRANCE ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 203. FRANCE ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 204. FRANCE ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
• TABLE 205. GERMANY ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 206. GERMANY ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 207. GERMANY ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 208. GERMANY ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 209. GERMANY ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 210. GERMANY ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 211. GERMANY ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
• TABLE 212. ISRAEL ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 213. ISRAEL ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 214. ISRAEL ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 215. ISRAEL ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 216. ISRAEL ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 217. ISRAEL ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 218. ISRAEL ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
• TABLE 219. ITALY ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 220. ITALY ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 221. ITALY ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 222. ITALY ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 223. ITALY ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 224. ITALY ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 225. ITALY ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
• TABLE 226. NETHERLANDS ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 227. NETHERLANDS ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 228. NETHERLANDS ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 229. NETHERLANDS ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 230. NETHERLANDS ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 231. NETHERLANDS ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 232. NETHERLANDS ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
• TABLE 233. NIGERIA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 234. NIGERIA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 235. NIGERIA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 236. NIGERIA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 237. NIGERIA ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 238. NIGERIA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 239. NIGERIA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
• TABLE 240. NORWAY ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 241. NORWAY ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 242. NORWAY ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 243. NORWAY ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 244. NORWAY ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 245. NORWAY ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 246. NORWAY ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
• TABLE 247. POLAND ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 248. POLAND ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 249. POLAND ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 250. POLAND ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 251. POLAND ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 252. POLAND ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 253. POLAND ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
• TABLE 254. QATAR ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 255. QATAR ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 256. QATAR ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 257. QATAR ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 258. QATAR ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 259. QATAR ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 260. QATAR ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
• TABLE 261. RUSSIA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 262. RUSSIA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 263. RUSSIA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 264. RUSSIA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 265. RUSSIA ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 266. RUSSIA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 267. RUSSIA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
• TABLE 268. SAUDI ARABIA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 269. SAUDI ARABIA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 270. SAUDI ARABIA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 271. SAUDI ARABIA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 272. SAUDI ARABIA ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 273. SAUDI ARABIA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 274. SAUDI ARABIA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
• TABLE 275. SOUTH AFRICA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 276. SOUTH AFRICA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 277. SOUTH AFRICA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 278. SOUTH AFRICA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 279. SOUTH AFRICA ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 280. SOUTH AFRICA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 281. SOUTH AFRICA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
• TABLE 282. SPAIN ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 283. SPAIN ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 284. SPAIN ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 285. SPAIN ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 286. SPAIN ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 287. SPAIN ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 288. SPAIN ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
• TABLE 289. SWEDEN ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 290. SWEDEN ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 291. SWEDEN ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 292. SWEDEN ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 293. SWEDEN ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 294. SWEDEN ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 295. SWEDEN ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
• TABLE 296. SWITZERLAND ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 297. SWITZERLAND ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 298. SWITZERLAND ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 299. SWITZERLAND ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 300. SWITZERLAND ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 301. SWITZERLAND ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 302. SWITZERLAND ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
• TABLE 303. TURKEY ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 304. TURKEY ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 305. TURKEY ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 306. TURKEY ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 307. TURKEY ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 308. TURKEY ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 309. TURKEY ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
• TABLE 310. UNITED ARAB EMIRATES ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 311. UNITED ARAB EMIRATES ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 312. UNITED ARAB EMIRATES ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 313. UNITED ARAB EMIRATES ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 314. UNITED ARAB EMIRATES ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 315. UNITED ARAB EMIRATES ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 316. UNITED ARAB EMIRATES ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
• TABLE 317. UNITED KINGDOM ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 318. UNITED KINGDOM ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 319. UNITED KINGDOM ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 320. UNITED KINGDOM ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 321. UNITED KINGDOM ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 322. UNITED KINGDOM ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 323. UNITED KINGDOM ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
• TABLE 324. ANOREXIA NERVOSA MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 325. ANOREXIA NERVOSA MARKET, FPNV POSITIONING MATRIX, 2023

The Anorexia Nervosa Market was valued at USD 94.65 million in 2023, expected to reach USD 106.87 million in 2024, and is projected to grow at a CAGR of 13.27%, to USD 226.52 million by 2030.

Anorexia Nervosa is a severe eating disorder characterized by an intense fear of gaining weight and a distorted body image, leading to restricted food intake and excessive weight loss. The necessity of addressing Anorexia Nervosa arises from its serious health implications, including malnutrition, heart issues, and even mortality. Application of market research in this domain includes understanding patient demographics, healthcare approaches, and treatment methodologies, while the end-use scope involves healthcare providers, mental health professionals, and pharmaceuticals. Key growth factors are the increasing awareness of mental health issues, advancements in therapeutic interventions, and supportive healthcare regulations. The potential opportunities lie in expanding telemedicine services for remote patient monitoring, pharmaceutical developments in effective medication, and personalized treatment plans leveraging AI and data analytics. However, the market growth faces limitations such as social stigma attached to mental health, high treatment costs, and a shortage of trained professionals. Logistical limitations and regulatory hurdles further complicate market dynamics.

To tap into these opportunities, businesses should focus on innovations in digital health platforms for continuous support and therapy, research into non-traditional and holistic treatment approaches like mindfulness and nutritional psychiatry, and collaborations with mental health advocacy groups. Additionally, mobile health technologies can target early-stage intervention and awareness among younger populations. The nature of the market is dynamic, with increasing competition and the need for comprehensive and accessible treatment solutions. Companies should enhance research on genetic factors impacting Anorexia Nervosa, contributing significantly to personalized medicine. Developing strategic partnerships with tech firms for advanced diagnostic tools like wearable technology can offer real-time health monitoring, thereby improving patient outcomes and engagement. Overall, integrating robust market strategies with advanced technology could significantly contribute to capturing market opportunities and overcoming existing challenges.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Anorexia Nervosa Market

The Anorexia Nervosa Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Expanding role of online and digital therapies in treating patients with Anorexia Nervosa
  • Government initiatives and funding for mental health research and treatment programs
  • Integration of multidisciplinary approaches involving nutritionists, psychologists, and medical doctors for comprehensive patient care
• Market Restraints
  • High stigma and lack of awareness surrounding anorexia nervosa impede early diagnosis and intervention
• Market Opportunities
  • Leveraging artificial intelligence to improve early detection and diagnosis of anorexia nervosa
  • Developing targeted nutritional programs to support recovery in anorexia nervosa patients
• Market Challenges
  • Limited effective treatment options for anorexia nervosa hinder widespread recovery

Porter's Five Forces: A Strategic Tool for Navigating the Anorexia Nervosa Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Anorexia Nervosa Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Anorexia Nervosa Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Anorexia Nervosa Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Anorexia Nervosa Market

A detailed market share analysis in the Anorexia Nervosa Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Anorexia Nervosa Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Anorexia Nervosa Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Anorexia Nervosa Market

A strategic analysis of the Anorexia Nervosa Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anorexia Nervosa Market, highlighting leading vendors and their innovative profiles. These include Alkermes plc, Amgen Inc., Biohaven Pharmaceuticals, Hologic, Inc., Johnson & Johnson, Merck & Co., Inc., Mindstrong Health, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., PsychoGenics Inc., Sanofi S.A., Sumitomo Pharma America, Inc., Takeda Pharmaceutical Company Limited., and Tonix Pharmaceuticals Holding Corp..

Market Segmentation & Coverage

This research report categorizes the Anorexia Nervosa Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Treatment Type, market is studied across Nutritional Counseling, Pharmacotherapy, and Psychotherapy. The Pharmacotherapy is further studied across Antidepressants, Antipsychotics, and Mood Stabilizers. The Psychotherapy is further studied across Cognitive Behavioral Therapy, Family-Based Therapy, and Interpersonal Psychotherapy.
• Based on Age Group, market is studied across Adults and Children & Adolescents.
• Based on Severity Level, market is studied across Mild, Moderate, and Severe.
• Based on End User, market is studied across Clinics, Homecare, and Hospitals.
• Based on Treatment Channel, market is studied across In-Patient and Out-Patient.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Expanding role of online and digital therapies in treating patients with Anorexia Nervosa
    • 5.1.1.2. Government initiatives and funding for mental health research and treatment programs
    • 5.1.1.3. Integration of multidisciplinary approaches involving nutritionists, psychologists, and medical doctors for comprehensive patient care
  • 5.1.2. Restraints
    • 5.1.2.1. High stigma and lack of awareness surrounding anorexia nervosa impede early diagnosis and intervention
  • 5.1.3. Opportunities
    • 5.1.3.1. Leveraging artificial intelligence to improve early detection and diagnosis of anorexia nervosa
    • 5.1.3.2. Developing targeted nutritional programs to support recovery in anorexia nervosa patients
  • 5.1.4. Challenges
    • 5.1.4.1. Limited effective treatment options for anorexia nervosa hinder widespread recovery
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Anorexia Nervosa Market, by Treatment Type

• 6.1. Introduction
• 6.2. Nutritional Counseling
• 6.3. Pharmacotherapy
  • 6.3.1. Antidepressants
  • 6.3.2. Antipsychotics
  • 6.3.3. Mood Stabilizers
• 6.4. Psychotherapy
  • 6.4.1. Cognitive Behavioral Therapy
  • 6.4.2. Family-Based Therapy
  • 6.4.3. Interpersonal Psychotherapy

7. Anorexia Nervosa Market, by Age Group

• 7.1. Introduction
• 7.2. Adults
• 7.3. Children & Adolescents

8. Anorexia Nervosa Market, by Severity Level

• 8.1. Introduction
• 8.2. Mild
• 8.3. Moderate
• 8.4. Severe

9. Anorexia Nervosa Market, by End User

• 9.1. Introduction
• 9.2. Clinics
• 9.3. Homecare
• 9.4. Hospitals

10. Anorexia Nervosa Market, by Treatment Channel

• 10.1. Introduction
• 10.2. In-Patient
• 10.3. Out-Patient

11. Americas Anorexia Nervosa Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Anorexia Nervosa Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Anorexia Nervosa Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
  • 14.3.1. A new EUR 2.7 million research initiative explores eating disorders, self-harm, and autism links to improve early diagnosis and interventions among youth
  • 14.3.2. Equip secures additional funding to expand virtual eating disorder treatment services
  • 14.3.3. UC San Diego launches clinical trial with USD 235,000 donation to explore ketogenic therapy effectiveness on anorexia nervosa relapse prevention
• 14.4. Strategy Analysis & Recommendation
  • 14.4.1. Merck & Co., Inc.

Companies Mentioned

• 1. Alkermes plc
• 2. Amgen Inc.
• 3. Biohaven Pharmaceuticals
• 4. Hologic, Inc.
• 5. Johnson & Johnson
• 6. Merck & Co., Inc.
• 7. Mindstrong Health
• 8. Otsuka Pharmaceutical Co., Ltd.
• 9. Pfizer Inc.
• 10. PsychoGenics Inc.
• 11. Sanofi S.A.
• 12. Sumitomo Pharma America, Inc.
• 13. Takeda Pharmaceutical Company Limited.
• 14. Tonix Pharmaceuticals Holding Corp.